The Pharmaceutical Benefits Advisory Committee (PBAC) has announced its recommendations for subsidised access to shingles vaccine Shingrix® for people aged 18 years and over at a moderate to high risk of infection, including some people living with MS.
The latest findings from the EVOLUTION trials indicated that evobrutinib did not achieve its main goal of reducing relapse rates over up to 156 weeks, when compared to teriflunomide in both studies.
AI-powered MRI analysis advances personalised MS care in new study.
MS Australia, together with MSWA, is thrilled to announce that a new clinical trial called PLATYPUS is set to be launched in Australia in 2024. This clinical trial is significant for two reasons: it aims to address the unmet need for treatments of progressive MS, and it utilises an exciting new clinical trial design called adaptive clinical trials.
CEO Rohan Greenland discusses MS Australia’s partnership with leading international MS societies to establish a new research collaboration under the Pathways to Cures roadmap with a focus on supercharging research within the END MS pillar.
Thousands meet in Milan to present the latest research findings in MS at the world’s largest MS research conference.
The first-ever adaptive clinical trial for Australians living with MS will seek to reverse neurological damage caused by progressive multiple sclerosis.
Promising developments were announced recently that could significantly elevate the engagement and support people with MS receive from the NDIS.
ATA188, a therapy aiming to retrain T-cells to combat EBV in progressive MS, falls short of expectations. However, the study provides valuable insights in the pursuit of new treatments for MS and highlights MS Australia’s pivotal role in innovative MS research.
